Kids & teens (for parents) · Pennsylvania
Studies for children and teens in Pennsylvania
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
71 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 3
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
Pfizer
- Location
- Bellevue, PA + 101 other US sites
- Eligibility basics
- Ages 1 mo–7 mo
- RecruitingHealthy volunteersPhase 3
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
Pfizer
- Location
- Sayre, PA + 20 other US sites
- Eligibility basics
- Ages 1 mo–4 mo
- RecruitingHealthy volunteers
Pupillometry in Identifying Risk of Postoperative Opioid-induced Respiratory Depression in Children Undergoing Tonsillectomy
NeurOptics Inc
- Location
- Pittsburgh, PA
- Eligibility basics
- Ages 3–17
- RecruitingPhase 3
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
Hoffmann-La Roche
- Location
- Smithfield, PA + 10 other US sites
- Eligibility basics
- Ages 1 mo–11
- RecruitingPhase 2
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Amgen
- Location
- Philadelphia, PA + 3 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 4
Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
Fresenius Kabi
- Location
- Pittsburgh, PA + 3 other US sites
- Eligibility basics
- Ages 1 mo–17
- RecruitingPhase 3
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
Amicus Therapeutics
- Location
- Pittsburgh, PA + 5 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 3
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
AbbVie
- Location
- Philadelphia, PA + 11 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2/Phase 3
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
BioMarin Pharmaceutical
- Location
- Philadelphia, PA + 7 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Eli Lilly and Company
- Location
- Smithfield, PA + 11 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 1/Phase 2
DFT383 in Pediatric Participants With Nephropathic Cystinosis
Novartis Pharmaceuticals
- Location
- Philadelphia, PA + 5 other US sites
- Eligibility basics
- Ages 2–5
- RecruitingPhase 2/Phase 3
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
Crinetics Pharmaceuticals Inc.
- Location
- Philadelphia, PA + 9 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Pfizer
- Location
- Hershey, PA + 18 other US sites
- Eligibility basics
- Ages 6–14
- RecruitingPhase 3
Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
Paradigm Therapeutics
- Location
- Philadelphia, PA + 3 other US sites
- Eligibility basics
- Ages 1 mo–12
- RecruitingPhase 3
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Vericel Corporation
- Location
- Philadelphia, PA + 10 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
AstraZeneca
- Location
- Pittsburgh, PA + 70 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Novartis Pharmaceuticals
- Location
- Pittsburgh, PA + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Merck Sharp & Dohme LLC
- Location
- Philadelphia, PA + 20 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
AbbVie
- Location
- Philadelphia, PA + 28 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
- Location
- Danville, PA + 23 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Eli Lilly and Company
- Location
- Philadelphia, PA + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent…
Bausch Health Americas, Inc.
- Location
- Scottdale, PA + 22 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie
- Location
- Philadelphia, PA + 25 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
- Location
- Pittsburgh, PA + 7 other US sites
- Eligibility basics
- Ages 2–17